• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Threshold Pharmaceuticals Inc. (THLD)

    -NasdaqCM
    3.07 Down 0.05(1.60%) Dec 19, 4:00PM EST
    |After Hours : 3.07 0.00 (0.00%) Dec 19, 4:48PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Threshold Pharmaceuticals Inc.
    170 Harbor Way
    Suite 300
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-474-8200
    Fax: 650-474-2529
    Website: http://www.thresholdpharm.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:61

    Business Summary 

    Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; and various earlier-stage clinical trials for therapeutic areas, including advanced leukemias, multiple myeloma, advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Threshold Pharmaceuticals, Inc. has a license and co-development agreement with Merck KGaA to co-develop and commercialize TH-302; and license agreement with Eleison Pharmaceuticals, Inc. for the development and commercialization of glufosfamide for the treatment of cancer in humans and animals. The company was founded in 2001 and is headquartered in South San Francisco, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Threshold Pharmaceuticals Inc.

    Corporate Governance 
    Threshold Pharmaceuticals Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 9. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 10; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Harold E. Selick Ph.D., 60
    Exec. Chairman and Chief Exec. Officer
    849.00K0.00
    Mr. Joel A. Fernandes , 44
    Principal Financial Officer, Principal Accounting Officer, VP of Fin. and Controller
    339.00K0.00
    Dr. Tillman E. Pearce M.D., 57
    Chief Medical Officer
    483.00K39.00K
    Mr. Robert L. Simon , 69
    Sr. VP of Regulatory Affairs & Quality Assurance
    406.00K0.00
    Dr. Nipun Davar Ph.D., MBA, 46
    VP of Pharmaceutical Devel. and Manufacturing
    356.00K20.00K
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders